%0 Journal Article
%T CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma
%A Carolina Cubillos-Zapata
%A Cristina Arribas-Jim¨¦nez
%A Eduardo L¨®pez-Collazo
%A Enrique Hern¨¢ndez-Jim¨¦nez
%A Jos¨¦ Avenda£¿o-Ortiz
%A Ra¨²l Cordoba
%A Teresa Villaescusa
%A V¨ªctor Moreno
%A V¨ªctor Toledano
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2016.1231290
%X In the three patients included in a phase I clinical trial ({"type":"clinical-trial","attrs":{"text":"NCT01421524","term_id":"NCT01421524"}}NCT01421524), we report the immunomodulatory effects and efficacy of CC-122, a novel pleiotropic pathway modifier compound originally developed for broad diffuse large B-cell lymphoma (DLBCL). The chemical structure of CC-122 includes the glutarimide moiety that is known to modulate the immune response. The immunomodulatory agents including lenalidomide represent a promising therapeutic strategy targeting tumors in B-cell lymphoid malignancies. We observed that CC-122 might regulate the NK phenotype and its activity due to the reduced accumulation of myeloid-derived suppressor cell and eventually decrease the Tregs subsets. Finally, the activation of T cells through co-stimulatory molecule (CD28) was detected as a delayed CC-122 effect. In this context, CC-122 arises as an alternative option for DLBCL patients refractory to the traditional chemotherapeutic agents
%K CC-122 treatment
%K DLBCL patients
%K immune response
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325046/